Amoéba
Pre-clinicalIt was by chance, during tests carried out as part of the biocide regulatory dossier, that we discovered the strong antifungal properties of the amoeba Willaertia magna C2c Maky.
Founded
2019
Focus
Infectious DiseaseMicrobiome
About
It was by chance, during tests carried out as part of the biocide regulatory dossier, that we discovered the strong antifungal properties of the amoeba Willaertia magna C2c Maky.
Funding History
4Total raised: $28M
Series C$12MBpifranceMay 15, 2021
Grant$2.5MEuropean CommissionMar 15, 2019
Series B$8MBpifranceSep 15, 2017
Series A$5.5MDemeter PartnersJun 15, 2015
Company Info
TypePrivate
Founded2019
LocationChassieu, France
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile